- Business
- Harbin Pharmaceutical Group Co., Ltd. (600664.SS) engages in the research, development, manufacturing, wholesale, and retail of pharmaceuticals primarily in China and internationally; the company operates across seven key business segments including antibiotics, small-molecule drug preparations, OTC and healthcare products, modern Chinese medicines, biopharmaceuticals, animal vaccines, and medicine circulation. It offers a broad portfolio of products such as zinc gluconate oral solutions, calcium iron zinc oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, recombinant human erythropoietin injections, ibuprofen granules, iron vitamin B12 oral solutions, ceftriaxone sodium injections, pediatric acetaminophen granules, Jiananxi Vitapak nutrition packages, lacidipine tablets, roxatidine acetate hydrochloride injections, penicillin and cephalosporin antibiotic preparations, as well as treatments for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, mineral and nutritional supplements, and traditional Chinese medicines; products are marketed under brands including Harbin Pharmaceutical, Sanjing, Gaizhonggai, Hutong, and Shiyitang. Founded in 1991 and headquartered at No. 7 Qunli Avenue, Daoli District, Harbin, Heilongjiang Province, China, the company maintains eight major production bases, holds 1,816 drug approvals and 74 health food approvals, employs over 10,000 staff, and extends operations to more than 50 countries with a focus on domestic pharmaceutical wholesale and retail alongside diversified activities in medical devices, medical aesthetics, biology, health technology, culture, science and technology, passenger transport, food, property, security, and pharmaceutical investments. Recent developments include the completion of its acquisition of substantially all assets of GNC Holdings Inc. in 2020 through subsidiary Harbin Pharmaceutical Group Holding Co., Ltd. for approximately $770 million to bolster its global health and wellness presence, a 2015 controlling stake acquisition in Wanbang Biopharmaceuticals to strengthen biopharmaceutical capabilities in diabetes and cardiovascular treatments, and a 2021 acquisition of Shenzhen Kexing Bioproducts Co., Ltd. to expand vaccine production; in 2025, a planned acquisition of a 20% stake was cancelled, while the company reported 2024 annual results and 2025 semi-annual revenue of RMB 8.125 billion alongside ongoing R&D investments supporting over 1,000 product varieties.